The abstract is read at the publisher; the summary is JClub's.
Advanced liver fibrosis and At-Risk MASH occur in 5% and 10%, respectively, of community patients with steatotic liver disease plus metabolic risk factors and/or excess alcohol consumption.
- Why it matters: Detecting these high-risk patients is critical because they face higher risk of liver decompensation and HCC, and At-Risk MASH identification helps target eligibility for pharmacotherapy.
- What they did: The work evaluates community screening pathways using sequential Fibrosis-4 Index plus elastography or direct serum fibrosis biomarkers, noting that existing At-Risk MASH biomarkers need broader community validation.
- The result: Primary-care screening studies show increased detection of unrecognized advanced liver disease and may reduce unnecessary specialist referrals, supporting wider implementation of evidence-based diagnostic pathways.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.